These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 34556152)
1. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway. Ji F; Zhang F; Zhang M; Long K; Xia M; Lu F; Li E; Chen J; Li J; Chen Z; Jing L; Jia S; Yang R; Hu Z; Guo Z J Hematol Oncol; 2021 Sep; 14(1):152. PubMed ID: 34556152 [TBL] [Abstract][Full Text] [Related]
2. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008 [No Abstract] [Full Text] [Related]
3. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment. Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886 [TBL] [Abstract][Full Text] [Related]
4. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Pal SK; Tran B; Haanen JBAG; Hurwitz ME; Sacher A; Tannir NM; Budde LE; Harrison SJ; Klobuch S; Patel SS; Meza L; Dequeant ML; Ma A; He QA; Williams LM; Keegan A; Gurary EB; Dar H; Karnik S; Guo C; Heath H; Yuen RR; Morrow PK; Agarwal N; Srour SA Cancer Discov; 2024 Jul; 14(7):1176-1189. PubMed ID: 38583184 [TBL] [Abstract][Full Text] [Related]
5. Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma. Panowski SH; Srinivasan S; Tan N; Tacheva-Grigorova SK; Smith B; Mak YSL; Ning H; Villanueva J; Wijewarnasuriya D; Lang S; Melton Z; Ghosh A; Dusseaux M; Galetto R; Heyen JR; Sai T; Van Blarcom T; Chaparro-Riggers J; Sasu BJ Cancer Res; 2022 Jul; 82(14):2610-2624. PubMed ID: 35294525 [TBL] [Abstract][Full Text] [Related]
6. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Sauer T; Parikh K; Sharma S; Omer B; Sedloev D; Chen Q; Angenendt L; Schliemann C; Schmitt M; Müller-Tidow C; Gottschalk S; Rooney CM Blood; 2021 Jul; 138(4):318-330. PubMed ID: 34323938 [TBL] [Abstract][Full Text] [Related]
7. CD70, a novel target of CAR T-cell therapy for gliomas. Jin L; Ge H; Long Y; Yang C; Chang YE; Mu L; Sayour EJ; De Leon G; Wang QJ; Yang JC; Kubilis PS; Bao H; Xia S; Lu D; Kong Y; Hu L; Shang Y; Jiang C; Nie J; Li S; Gu Y; Sun J; Mitchell DA; Lin Z; Huang J Neuro Oncol; 2018 Jan; 20(1):55-65. PubMed ID: 28651374 [TBL] [Abstract][Full Text] [Related]
8. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models. Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023 [TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Wang QJ; Yu Z; Hanada KI; Patel K; Kleiner D; Restifo NP; Yang JC Clin Cancer Res; 2017 May; 23(9):2267-2276. PubMed ID: 27803044 [No Abstract] [Full Text] [Related]
10. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. Wu G; Guo S; Luo Q; Wang X; Deng W; Ouyang G; Pu JJ; Lei W; Qian W Front Immunol; 2023; 14():1093750. PubMed ID: 36845088 [TBL] [Abstract][Full Text] [Related]
11. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487 [TBL] [Abstract][Full Text] [Related]
12. IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts. Van den Eynde A; Gehrcken L; Verhezen T; Lau HW; Hermans C; Lambrechts H; Flieswasser T; Quatannens D; Roex G; Zwaenepoel K; Marcq E; Joye P; Cardenas De La Hoz E; Deben C; Gasparini A; Montay-Gruel P; Le Compte M; Lion E; Lardon F; Van Laere S; Siozopoulou V; Campillo-Davo D; De Waele J; Pauwels P; Jacobs J; Smits E; Van Audenaerde JRM J Hematol Oncol; 2024 Feb; 17(1):8. PubMed ID: 38331849 [TBL] [Abstract][Full Text] [Related]
13. STING agonist promotes CAR T cell trafficking and persistence in breast cancer. Xu N; Palmer DC; Robeson AC; Shou P; Bommiasamy H; Laurie SJ; Willis C; Dotti G; Vincent BG; Restifo NP; Serody JS J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33382402 [TBL] [Abstract][Full Text] [Related]
14. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation. Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469 [TBL] [Abstract][Full Text] [Related]
15. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Wang QJ; Hanada K; Robbins PF; Li YF; Yang JC Cancer Res; 2012 Dec; 72(23):6119-29. PubMed ID: 23071066 [TBL] [Abstract][Full Text] [Related]
16. Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma. Benhamouda N; Sam I; Epaillard N; Gey A; Phan L; Pham HP; Gruel N; Saldmann A; Pineau J; Hasan M; Quiniou V; Nevoret C; Verkarre V; Libri V; Mella S; Granier C; Broudin C; Ravel P; De Guillebon E; Mauge L; Helley D; Jabla B; Chaput N; Albiges L; Katsahian S; Adam J; Mejean A; Adotevi O; Vano YA; Oudard S; Tartour E Clin Cancer Res; 2022 Nov; 28(22):4983-4994. PubMed ID: 36067339 [TBL] [Abstract][Full Text] [Related]
17. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Shaffer DR; Savoldo B; Yi Z; Chow KK; Kakarla S; Spencer DM; Dotti G; Wu MF; Liu H; Kenney S; Gottschalk S Blood; 2011 Apr; 117(16):4304-14. PubMed ID: 21304103 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma. Zhu G; Zhang J; Zhang Q; Jin G; Su X; Liu S; Liu F Cancer Immunol Immunother; 2022 Oct; 71(10):2433-2448. PubMed ID: 35249119 [TBL] [Abstract][Full Text] [Related]
19. Anti-tumor efficacy of human anti-c-met CAR-T cells against papillary renal cell carcinoma in an orthotopic model. Mori JI; Adachi K; Sakoda Y; Sasaki T; Goto S; Matsumoto H; Nagashima Y; Matsuyama H; Tamada K Cancer Sci; 2021 Apr; 112(4):1417-1428. PubMed ID: 33539630 [TBL] [Abstract][Full Text] [Related]
20. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Adam PJ; Terrett JA; Steers G; Stockwin L; Loader JA; Fletcher GC; Lu LS; Leach BI; Mason S; Stamps AC; Boyd RS; Pezzella F; Gatter KC; Harris AL Br J Cancer; 2006 Aug; 95(3):298-306. PubMed ID: 16892042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]